BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company, focuses on developing and commercializing immunomodulation therapies for infectious diseases primarily in Israel. Its product candidate is M-001, a synthetic peptide-based protein, which has completed Phase II clinical trials that is used for treating seasonal and pandemic strains of the influenza virus. The company was founded in 2003 and is headquartered in Ness Ziona, Israel.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone972-8930-2529
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees14
OptionableNot Optionable
BIONDVAX PHARMA/S (NASDAQ:BVXV) Frequently Asked Questions
What is BIONDVAX PHARMA/S's stock symbol?
BIONDVAX PHARMA/S trades on the NASDAQ under the ticker symbol "BVXV."
When is BIONDVAX PHARMA/S's next earnings date?
Has BIONDVAX PHARMA/S been receiving favorable news coverage?
News coverage about BVXV stock has trended somewhat positive recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. BIONDVAX PHARMA/S earned a coverage optimism score of 1.2 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 2.0 out of 10, meaning that recent press coverage is very unlikely to have an effect on the company's share price in the near term.
Who are some of BIONDVAX PHARMA/S's key competitors?
Some companies that are related to BIONDVAX PHARMA/S include Organovo (ONVO), Pluristem Therapeutics (PSTI), Champions Oncology (CSBR), Outlook Therapeutics (OTLK), Nantkwest (NK), Brainstorm Cell Therapeutics (BCLI), Aptose Biosciences (APTO), Idera Pharmaceuticals (IDRA), INmune Bio (INMB), Cidara Therapeutics (CDTX), AVITA MED LTD/S (AVMXY), BioCardia (BCDA), Applied Genetic Technologies (AGTC), Proteon Therapeutics (PRTO) and Oncobiologics (ONS).
Who are BIONDVAX PHARMA/S's key executives?
BIONDVAX PHARMA/S's management team includes the folowing people:
- Dr. Ron Babecoff, Co-Founder, CEO, Pres & Director (Age 57)
- Mr. Uri Ben-Or CPA, M.B.A., CPA, MBA, Chief Financial Officer (Age 49)
- Dr. Tamar Ben Yedidia, Chief Scientific Officer (Age 55)
- Dr. Shimon Hassin, Chief Operating Officer
- Mr. Elad Mark, Head of Site & Process Devel.
When did BIONDVAX PHARMA/S IPO?
(BVXV) raised $10 million in an initial public offering (IPO) on Tuesday, May 12th 2015. The company issued 1,400,000 shares at $7.32 per share. Aegis Capital Corp served as the underwriter for the IPO.
How do I buy shares of BIONDVAX PHARMA/S?
Shares of BVXV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is BIONDVAX PHARMA/S's stock price today?
One share of BVXV stock can currently be purchased for approximately $5.31.
How big of a company is BIONDVAX PHARMA/S?
BIONDVAX PHARMA/S has a market capitalization of $34.70 million. The company earns $-9,960,000.00 in net income (profit) each year or ($1.98) on an earnings per share basis. BIONDVAX PHARMA/S employs 14 workers across the globe.
What is BIONDVAX PHARMA/S's official website?
How can I contact BIONDVAX PHARMA/S?
BIONDVAX PHARMA/S's mailing address is 14 Einstein Street, Nes Ziona L3, 74036. The company can be reached via phone at 972-8930-2529 or via email at [email protected]
MarketBeat Community Rating for BIONDVAX PHARMA/S (NASDAQ BVXV)
MarketBeat's community ratings are surveys of what our community members think about BIONDVAX PHARMA/S and other stocks. Vote "Outperform" if you believe BVXV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BVXV will underperform the S&P 500 over the long term. You may vote once every thirty days.
